AbbVie Inc.
ABBV · As of 2026-10-15
$283.40
·
2.44%
Latest close & trailing twelve-month yield
Adjusted close price
Annualized Compounded Stock Growth
Annual dividends — last 10 years
Stock Volatility
Details
Company overview — ABBV
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description |
ShowAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address |
Show1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2026-06-30 |
| MarketCapitalization | $484.83 Billion |
| EBITDA | $30.76 Billion |
| PERatio | 77.5 |
| PEGRatio | 0.542 |
| BookValue | -3.359 |
| DividendPerShare | 6.83 |
| DividendYield | 0.0243 |
| EPS | 3.54 |
| RevenuePerShareTTM | 36.39 |
| ProfitMargin | 9.80% |
| OperatingMarginTTM | 40.00% |
| ReturnOnAssetsTTM | 10.50% |
| ReturnOnEquityTTM | 62.30% |
| RevenueTTM | $64.39 Billion |
| GrossProfitTTM | $46.87 Billion |
| DilutedEPSTTM | 3.54 |
| QuarterlyEarningsGrowthYOY | 2.904 |
| QuarterlyRevenueGrowthYOY | 0.102 |
| AnalystTargetPrice | 282.61 |
| AnalystRatingStrongBuy | 8 |
| AnalystRatingBuy | 16 |
| AnalystRatingHold | 5 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 1 |
| TrailingPE | 77.5 |
| ForwardPE | 16.39 |
| PriceToSalesRatioTTM | 7.53 |
| PriceToBookRatio | 50.46 |
| EVToRevenue | 8.27 |
| EVToEBITDA | 27.34 |
| Beta | 0.228 |
| 52WeekHigh | 283.66 |
| 52WeekLow | 188.25 |
| 50DayMovingAverage | 259.5 |
| 200DayMovingAverage | 232.91 |
| SharesOutstanding | 1,767,117,000 |
| SharesFloat | 1,763,954,000 |
| PercentInsiders | 0.110 |
| PercentInstitutions | 77.340 |
| DividendDate | 2026-11-16 |
| ExDividendDate | 2026-10-15 |